Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

Biotech Beyond Borders Report finds that the biotech industry is grappling with a wave of challenges, including ongoing ...

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

This Biotech Stock Is Up 85%. FDA Has Agreed to Review a Skin Cancer Drug. Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

In 2023, ReNAgade Therapeutics launched with $300 million to exploit an “all in one” technology solution for RNA-based therapies. That same year, Tome Biosciences emerged from stealth with $213 ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

Biotech firms develop drugs from living organisms; pharma from chemicals. Biotech products require a Biologics License Application for FDA approval. Investing focus should be on the long-term ...